{"prompt": "['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', '(DPI). UMEC/VI at a dose of 62.5/25mcg once-daily is marketed in the United States', 'TM', '(US) and Europe under the trade name ANORO ELLIPTA.', 'UMEC (62.5 mcg) inhalation powder is marketed in the United States (US) and Europe', 'under', 'the', 'trade name INCRUSET ELLIPTA. UMEC (62 1.5mcg) is indicated as', 'a', 'maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.', 'UMEC (62.5 mcg) improves forced expiratory volume in one second (FEV1), dyspnea', 'and HRQoL whether used as monotherapy [Trivedi, 2014; Feldman, 2016] or as an add', 'on to fluticasone propionate and vilanterol (FF/VI) [Siler, 2015]. Salmetrol (50 mcg)', 'DISKUS is a long-acting broncholdilator that has long been used for the maintenance', 'treatment of COPD [Tashkin, 2010].', 'Clinically important deterioration (CID) is a novel, exploratory composite endpoint', 'which assesses individual deteriorations in lung function and in patient PROs defined by', 'the accepted minimal clinically important difference (MCID), as well as the incidence of', 'moderate to severe exacerbations [Singh, 2016], (Section 7.3.5). CID will be analysed to', 'determine whether UMEC/VI (62.5/25mcg) therapy provides greater clinical stability as', 'compared with UMEC and salmeterol monotherapies.', '3.', 'OBJECTIVE(S) AND ENDPOINT(S)', 'Objectives', 'Endpoints', 'Primary', 'To compare the effect of UMEC/VI', 'Change from baseline in trough Forced', '(62.5/25 mcg once daily) with UMEC', 'Expiratory Volume in One Second', '(62.5 mcg once daily) on lung function', '(FEV1) at week 24', 'Secondary', 'To compare UMEC/VI (62.5/25 mcg', 'Change from baseline in self', 'once daily), UMEC (62.5 mcg once', 'administered computerised (SAC)', 'daily) with salmeterol (50 mcg twice', 'transient dyspnea index (TDI)', 'daily) on patient reported outcomes', '(PROs)', 'Percentage of TDI responders', 'according to SAC TDI score. A', 'responder is defined as a >1 unit', 'improvement in SAC TDI score', 'Assessment of respiratory daily', 'symptoms over 24 weeks using', 'Evaluating Respiratory Symptoms-', 'COPD (E-RS) and its subscales', '(breathlessness, cough and sputum and', 'chest symptoms)', 'Percentage of E-RS responders', 'according to E-RS score (defined as', 'reduction in E-RS score of >2 or >3.35', 'units) from baseline', '15']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Objectives', 'Endpoints', \"Change from baseline in St George's\", 'Respiratory Questionnaire (SGRQ-C)', 'Percentage of responders according to', 'SGRQ-C total score (defined as a 4', 'point or greater reduction from', 'baseline)', 'Change from baseline in COPD', 'assessment test (CAT)', 'Percentage of responders according to', 'CAT (defined as a >2 unit improvement', 'in score from baseline)', 'Other', 'To compare UMEC/VI (62.5/25 mcg', 'Rate of mild, moderate or severe', 'once daily), UMEC (62.5 mcg once', 'exacerbations', 'daily) with salmeterol (50 mcg twice', 'daily) on other COPD efficacy measures', 'Time to first mild, moderate or severe', 'exacerbation', 'Rate of moderate or severe', 'exacerbation', 'Time to moderate or severe', 'exacerbation', 'Time to severe exacerbations', 'Time to clinically important', 'deterioration (CID) composite endpoint', 'Time to clinically important', 'deterioration composite endpoint', 'excluding FEV1', 'Rescue albuterol/salbutamol use,', '(percentage of rescue-free days and', 'mean number of Inhalations/day', 'captured by the electronic diary', '(eDiary) over 24 weeks', 'Inspiratory capacity (IC)', 'Full Vital capacity (FVC)', '16']\n\n###\n\n", "completion": "END"}